Sarepta at new high on eteplirsen, Prosensa's drisapersen data
This article was originally published in Scrip
Executive Summary
Exactly one year after Sarepta Therapeutics saw its value triple based on 48-week, Phase II clinical trial data for its Duchenne muscular dystrophy (DMD) drug, the company's stock price reached a new high on 3 October based on the latest six-minute walk test (6MWT) and dystrophin results for eteplirsen and the competing DMD therapy drisapersen.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).